GIOTRIF in First Line Therapy of Advanced NSCLC With EGFR-mutations
Status:
Completed
Trial end date:
2018-12-31
Target enrollment:
Participant gender:
Summary
This observational study will investigate the efficacy, safety, tolerability and symptom
control of GIOTRIF (Afatinib) in daily routine first-line therapy in patients with locally
advanced or metastatic NSCLC harboring EGFR-mutations. Eligible NSCLC patients, for whom the
treating physician has decided to initiate treatment with GIOTRIF in first line according to
the local label, will be followed up for approximately 24 months.